Werewolf Therapeutics Inc
NASDAQ:HOWL

Watchlist Manager
Werewolf Therapeutics Inc Logo
Werewolf Therapeutics Inc
NASDAQ:HOWL
Watchlist
Price: 0.5509 USD -5.72% Market Closed
Market Cap: 26.7m USD

Wall Street
Price Targets

HOWL Price Targets Summary
Werewolf Therapeutics Inc

Wall Street analysts forecast HOWL stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HOWL is 6.29 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

Lowest
Price Target
3.03 USD
450% Upside
Average
Price Target
6.29 USD
1 042% Upside
Highest
Price Target
10.5 USD
1 806% Upside
Werewolf Therapeutics Inc Competitors:
Price Targets
ARMP
Armata Pharmaceuticals Inc
92% Upside
688331
RemeGen Co Ltd
10% Downside
EDIT
Editas Medicine Inc
141% Upside
HRTX
Heron Therapeutics Inc
208% Upside
ELDN
Eledon Pharmaceuticals Inc
294% Upside
NIOX
Niox Group PLC
20% Upside
ABNX
Abionyx Pharma SA
198% Upside
CRBU
Caribou Biosciences Inc
627% Upside

Revenue
Forecast

Revenue Estimate
Werewolf Therapeutics Inc

The compound annual growth rate of Werewolf Therapeutics Inc's revenue for the next 4 years is 77%.

N/A
Past Growth
77%
Estimated Growth
Estimates Accuracy
-2%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Werewolf Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Net Income
Forecast

Net Income Estimate
Werewolf Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-35%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is HOWL's stock price target?
Price Target
6.29 USD

According to Wall Street analysts, the average 1-year price target for HOWL is 6.29 USD with a low forecast of 3.03 USD and a high forecast of 10.5 USD.

What is Werewolf Therapeutics Inc's Revenue forecast?
Projected CAGR
77%

The compound annual growth rate of Werewolf Therapeutics Inc's revenue for the next 4 years is 77%.

Back to Top